Make us your home page

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Q&A | Dr. Leslie W. Miller

Matters of the heart

Dr. Leslie W. Miller, who takes over as director of the University of South Florida Cardiovascular Clinical and Research Integrated Strategic Program, wants to focus on research and new therapies, including stem cells.


Dr. Leslie W. Miller, who takes over as director of the University of South Florida Cardiovascular Clinical and Research Integrated Strategic Program, wants to focus on research and new therapies, including stem cells.


Dr. Leslie W. Miller hasn't yet started his new job at USF Health. But his vision already is clear: turning Tampa into a major destination for patients seeking the latest procedures, drugs and devices to treat damaged hearts. • "I don't dream small," says Miller, who will lead a new, expanded department of cardiovascular sciences at USF Health. "I really want to see this as the dominant institution in the state with niches where we're a national leader."

Miller, 62, comes to USF from Washington Hospital Center and Georgetown University School of Medicine in Washington, D.C.

A researcher and clinician for 28 years, Miller specializes in the treatment of heart failure and the use of ventricular assist devices — mechanical heart pumps known as VADs — in heart transplant patients. At USF, Miller hopes to move cardiac research forward at a rapid clip, particularly in the use of stem cells to regrow damaged tissue, and personalized medicine based on a patient's gene profile.

"Heart disease is still the No. 1 killer of Americans,'' he said in an interview at USF on Monday. "By age 65, 10 percent of the population is afflicted with heart failure. We're going to take a very aggressive tack to have these new therapies ready for patients in a very short period of time.''

Miller's first day on the job is Sept. 15, but while in Tampa this week for meetings, he sat down with the Times to discuss his goals for the program he'll oversee and how it will benefit patients in the Tampa Bay area and beyond.

How will cardiac care at USF Health, Tampa General Hospital (USF's primary teaching affiliate) and in the Tampa Bay area change with your arrival?

To be sure, I'm joining a team. And I think it's going to be an amazing fit with all that's already going on here and the talented people who are here. My focus is going to be new research, new therapies. What will that mean to the people of Tampa Bay? It will start with conferences and educational opportunities for medical professionals; health fairs, lectures and events for the general public; training the best and the brightest in medicine to increase the quality of health care in the community. I plan to spend time each week visiting community cardiologists, seeing their most difficult heart failure patients and letting them know what USF has to offer. One of the new things that will be coming here is the Regenerative Medicine Institute. It really is part of what brought me here. Using stem cells to repair the heart — I'm really interested in putting them in the patient to regain heart function.

You'll be working with USF's Paul Sanberg, who has done a lot of research using stem cells for brain repair.

Yes, we really hit it off. His work with umbilical cord cells is very provocative because they don't require an embryo. Those umbilical cord cells have not been used in patients with heart failure. That's the cell I want to try to go after early on and try and put those in heart failure patients who are candidates for ventricular assist devices. At the time you put in the VAD, the chest is open, it takes us about five minutes to inject the stem cells. Then, when the donor heart is found we'll have the benefit of studying the heart we treated to find out how the stem cells reacted, what dose is most effective, what are the side effects. We've never been able to take the entire heart out of a patient and study it in total. So it will markedly advance the research.

How far away is that from happening here?

That will happen within the year, I hope. There will be a trial here with stem cells within the next six months, I'm pretty comfortable with that. Will it meet the potential that everybody hopes for? That we can use stem cells in diabetes and Parkinson's disease and Alzheimer's and really have local tissue regenerate? We think that the data thus far suggests that it's possible. And we will have a whole institute to try to understand how we get there. That's the goal.

What else can we expect to see?

Personalized medicine. We can now understand racial differences, gender differences, age differences and how you're likely to respond to heart failure medications. So we'll have your genomic profile and say, "Okay, you have this alteration, you probably wouldn't respond to that drug, you may respond to this drug.'' Or the ultimate is to be able to tell you, "You have a predisposition to diabetes or heart disease and we can decide how to intervene on that early.''

Sum it all up.

We'll have stem cell therapy, gene therapy, new drug therapies and other research drugs, four kinds of ventricular assist devices, we have a spectacular heart transplant program. So I don't think you can go anywhere in the country and get something that isn't going to be offered here. That's my real goal.

Irene Maher can be reached at [email protected]

at a glance

Dr. Leslie W. Miller

Training: University of Missouri School of Medicine; resident, Washington University and Barnes Hospital; cardiology fellow, Peter Bent Brigham Hospital, Boston.

Previous posts: chief of integrated cardiology programs, Washington Hospital Center and Georgetown University School of Medicine; Walters Chair in Cardiovascular Medicine at Georgetown University; director of heart failure/transplant and VAD program, Washington Hospital Center.

Title at USF: director/CEO of the University of South Florida Cardiovascular Clinical and Research Integrated Strategic Program.

Matters of the heart 09/01/10 [Last modified: Thursday, September 2, 2010 5:57pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times


Join the discussion: Click to view comments, add yours

  1. Paul Rodgers replacing ZZ Top on Ribfest 2017 lineup


    In looking to replace the ailing ZZ Top, Ribfest found some good company in Bad Company.

    Paul Rodgers
  2. Some teachers allege 'hostile and racially charged' workplace at Pinellas Park Middle


    PINELLAS PARK — Two black teachers at Pinellas Park Middle have requested transfers out of the school, alleging the work environment there has become "hostile and racially charged."

    Pinellas Park Middle School at 6940 70th Ave N, where some black teachers have alleged they were treated with hostility by colleagues after starting a tutoring program for black students. Just 22 percent of black students were proficient in English language arts in last spring's state tests. Two black teachers have asked to be transfered, according to a letter from two local chapters of the NAACP. [CHERIE DIEZ   |   Times]

  3. Editorial: The unknown price tags in the mayor's race


    St. Petersburg Mayor Rick Kriseman has been busy promoting all sorts initiatives in the months leading up to the Nov. 7 election, doubling down on his progressive agenda without spending much money or generating much controversy. But make no mistake, the cost will come due after the election. Without a change in …

    The mayor is determined to get artist Janet Echelman to create a sculpture for the new Pier. But the cost would be much higher than what is allocated. Above is Echelman’s As If It Were Already Here in Boston.
  4. Massachusetts firm buys Tampa's Element apartment tower

    Real Estate

    TAMPA — Downtown Tampa's Element apartment tower sold this week to a Massachusetts-based real estate investment company that plans to upgrade the skyscraper's amenities and operate it long-term as a rental community.

    The Element apartment high-rise at 808 N Franklin St. in downtown Tampa has been sold to a Northland Investment Corp., a Massachusetts-based real estate investment company. JIM DAMASKE  |  Times
  5. Judge won't cut prison term of man who pleads obesity


    TAMPA — A claim of obesity won't shave time off a Tampa man's prison sentence.

    Duane Crithfield and Stephen Donaldson Sr. were sentenced to prison after marketing a fraudulent offshore tax strategy known as a "Business Protection Plan" to medical practices, offering doctors and others coverage against unlikely events such as a kidnapping.